Pseudomonas aeruginosa toxin ExoU as a therapeutic target in the treatment of bacterial infections

58Citations
Citations of this article
111Readers
Mendeley users who have this article in their library.

Abstract

The opportunistic pathogen Pseudomonas aeruginosa employs the type III secretion system (T3SS) and four effector proteins, ExoS, ExoT, ExoU, and ExoY, to disrupt cellular physiology and subvert the host’s innate immune response. Of the effector proteins delivered by the T3SS, ExoU is the most toxic. In P. aeruginosa infections, where the ExoU gene is expressed, disease severity is increased with poorer prognoses. This is considered to be due to the rapid and irreversible damage exerted by the phospholipase activity of ExoU, which cannot be halted before conventional antibiotics can successfully eliminate the pathogen. This review will discuss what is currently known about ExoU and explore its potential as a therapeutic target, highlighting some of the small molecule ExoU inhibitors that have been discovered from screening approaches.

Cite

CITATION STYLE

APA

Foulkes, D. M., McLean, K., Haneef, A. S., Fernig, D. G., Winstanley, C., Berry, N., & Kaye, S. B. (2019, December 1). Pseudomonas aeruginosa toxin ExoU as a therapeutic target in the treatment of bacterial infections. Microorganisms. MDPI AG. https://doi.org/10.3390/microorganisms7120707

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free